Mechanisms of therapeutic CDK4/6 inhibition in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastatic breast cancer treatment has advanced with cyclin-dependent kinase (CDK) 4/6 inhibitors targeting cell cycle machinery.
• Derangements in cyclin D1, CDK4/6, and retinoblastoma expression are common in breast cancer, suggesting therapeutic potential in targeting this axis.
• Complex interplay exists between cell cycle regulation, estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) signaling.

Purpose of the Study:

• To review the mechanism of action of CDK4/6 inhibitors in breast cancer.
• To discuss the synergistic use of CDK4/6 inhibitors with endocrine therapy.
• To explore mechanisms of resistance to endocrine therapy and novel CDK4/6 inhibitors in development.

Main Methods:

• Review of preclinical evidence from cell lines and animal models.
• Analysis of studies investigating the interplay between cell cycle and ER/HER2 signaling.
• Examination of US Food and Drug Administration-approved CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib).

Main Results:

• CDK4/6 inhibitors interrupt cell cycle progression and hormone signals driving malignant cell proliferation.
• Estrogen receptor activity upregulates cyclin D1, which can also activate the estrogen receptor.
• Current CDK4/6 inhibitors show promise in hormone receptor-positive breast cancer, unlike earlier nonspecific CDK inhibitors with toxicities.

Conclusions:

• CDK4/6 inhibitors represent a significant advancement in treating metastatic breast cancer.
• Understanding the complex cell cycle and signaling pathway interactions informs therapeutic strategies and resistance mechanisms.
• Ongoing research into novel CDK4/6 inhibitors holds potential for refining future breast cancer treatments.